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Background: Nanosecond pulsed electric fields (nsPEFs) showed an inhibitory effect on proliferation of malignant 
melanoma. In this study, the growth of melanoma were inhibited by changing the systemic immunity.
Material and Methods: C57BL/6 mice with B16 malignant were exposed to 200 pulses of 100 ns duration, 30kV/
cm. The mice were executed four days later. T lymphocyte has been extracted from spleen. Cell viability was 
evaluated by CCK-8 assay. CD3+CD4+T cells, CD3+CD8+T cells, regulatory T cells (Treg) and myeloid-derived 
suppressor cells (MDSC) were analyzed by flow cytometry. TNF-α, IL-2, IL-10, TGF-β, IFN–γ levels in superna-
tants were assessed by ELISA.
Results: C57 malignant melanoma model were established successfully. After the treatment of nsPEFs(30 kV/cm 
100 ns 200p), the numbers of T lymphocytes were increased. CD3+CD4+T cells changed from 48% to 51.2%; 
CD3+CD8+T lymphocytes increased from 39.6% to 40.4%. Treg cells reduced from 4.3% to 2.4%, MDSC de-
creased by 39.0% to 19.7%. In addition, the level of TNF-α, IL-2 were increased (P < 0.05) and the level of IL-10 
were decreased (P < 0.05) and the level of TGF-β and IFN-γ remained stable (P > 0.05).
Conclusions: Tumor growth can be effectively inhibited by nsPEFs in vivo, which activate targets of immune re-
spones, accumulation of inflammatory cells and immune cytokines.  
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Introduction
Cancer is the leading cause of death in developed coun-
tries and the second leading cause of death in develop-
ing countries (1). At present, medical treatment methods 
for tumors mainly include surgical resection, radiation 
therapy, chemotherapeutic drug treatment (2,3), tradi-
tional Chinese medicine treatment (4), and molecular 
immunotherapy (5), but these treatments have different 
degrees of limitations and side effects. Thus seeking for 
a new treatment is imminent.
The occurrence and development of tumors are closely 
related to the immune system, with the further develop-
ment of the disease, tumor cells and immune cells com-
peted in the host body. In the immune system, in order 
to prevent autoimmune reactions from occurring, some 
immune cells inhibit the immune response (6) such as 
MDSCs and regulatory T cells. Due to the presence of 
these cells, the balance of the immune system is main-
tained. IL-10 and TGF-β cytokines create an immune 
escape microenvironment during the development of 
tumors (7) , it exists long-term with tumor patients. In a 
word, the purpose of tumor immunotherapy is to stimu-
late or mobilize the body’s immune system to enhance 
the tumor microenvironment against tumor immunity, 
thereby controlling and killing tumor cells (8).
In recent years, nanosecond pulsed electric fields 
(nsPEFs) with short pulse duration, low energy density 
and non-thermal effects have caused a lot of attention. 
It can induce tumor cell apoptosis (9), anti-angiogenesis 
(10), thereby inhibiting tumor recurrence and metasta-
sis. Cellular and animal models studies  have confirmed 
the biological characteristics of tumor ablation, such as 
malignant melanoma (11), human osteosarcoma (12), 
pancreatic cancer (13). As a novel tumor therapy, it has 
shown a clinical perspective. But the specific relation-
ship between systemic immune and nsPEFs is unclear. 
So in this study we will establish models of  C57 malig-
nant melanoma, and to explore the relationship between 
nsPEFs and systemic immunity. We will provide a new 
idea for tumor immunotherapy.
Material and Methods
-Reagents
TNF-α, IL-2, TGF-β, IFN-γ, IL-10 ELISA kit (eBiosci-
ence, USA), CCK-8, lymphocyte separation medium, 
DMSO (Sigma, USA), DMEM, RPMI 1640, and FBS 
(Hyclone, USA), trypsin (Gibco, USA),  Anti - Mouse 
CD3 - PE - Cy5, Anti - Mouse CD4 - PE, Anti - Mouse 
CD8 - FITC, Anti - Mouse CD4 - PE - Cy5, Anti - 
Mouse CD127 - Alexa Fluor 488, Anti - Mouse CD25 
- PE, Anti - MouseCD11b - PE - Cyanine5, Anti-Mouse 
Ly-6G (Gr-1)-PE (eBioscience, USA).    
-Instrument
Nanosecond pulse device was developed by Academy 
for Advanced Interdisciplinary Studies, PKU. Proto-
type parameters: 30 kV peak voltage, pulse width 100 
ns, frequency of 1 Hz. 
-Mice and cell  
C57 mice (female), 6-8 weeks, (18-20) g, were purchased 
from Charles river company, B16 malignant melanoma 
cell lines was provided by the basic medical college of 
Peking medical. Twenty C57 mice were inoculated sub-
cutaneously with B16 melanoma cells on the back. The 
mice were divided into two groups: 10 tumor-bearing 
mice of nsPEF untreated group (control group) and 10 
mice of nsPEF-treated group (therapy group). Each ex-
periment repeated three times.
-The selection of experimental parameters
1x106/ml single cell suspension, take 0.2 mL cell sub-
cutaneous inoculation into back after the mice was 
anesthesiaed by 1% pentobarbital sodium solution. the 
tumor (distribute in the subcutaneous nonmetastatic 
stage. CLARK IV: the Breslow thickness 1.51~3.00mm) 
were treated at 30 KV/cm 100 ns 300pulse, 200 pulse 
and 100 pulse, respectively. After four days, observe the 
ablation of the mice. 
-T lymphocyte preparation
After the mice in each group were sacrificed, the spleen 
was taken aseptically, placed on a clean bench, rinsed 
with physiological saline and cut into pieces, ground 
with a sterile syringe needle, filtered through a 200-
mesh sterile filter and the cell filtrate was collected and 
centrifuged at 1000r/min Centrifuged 5min, the super-
natant was discarded in the sedimentation cells added 
2mL red blood cell lysate mix, let stand 5min, the su-
pernatant was centrifuged, the precipitate was mixed 
lymphocytes. 
-CCK-8 detect the proliferation of T cells 
Executed the mice, separate the spleen, extract T lym-
phocytes to cultivate, adjust the cell density of 5 x 104/
mL, vaccination in 96 - well cell culture plates, culti-
vate after 24 h, 48 h, to add the CCK-8 fluid, 37°C for 2 
h incubation. 450 nm wavelength measured the optical 
density value of the cell. The proliferation rate = (OD 
nsPEFs – OD control)/OD control. 
-Flow cytometry instrument to analysis CD3+CD4 +T 
cells, CD3+CD8+T cells, Treg and MDSC 
Adjust the density of  lymphocyte cell to 1x105/mL 
take 100 uL spleen cell suspension, add antibody Anti 
- Mouse CD3 - PE - Cy5, Anti - Mouse CD4 - PE, Anti 
- Mouse CD8 - FITC detect CD3 +, CD4 + T cells and 
CD3 + CD8 + T cells, Anti - Mouse CD4 - PE - Cy 
Anti - Mouse CD127 - Alexa Fluor 488, Anti-Mouse 
CD25–PE to test Treg cells; Anti - Mouse CD11b - PE 
- Cyanine5, Anti-Mouse Ly-6G (Gr-1)-PE test MDSC 
cells, blending, avoid light, cultivate the cells in 4°C for 
30 min, centrifugal, computer test.
-ELISA to analysis TNF-α, IFN-γ, IL-2, TGF-β, IL-10  
Pick the eyeball of mice for bloodletting, collect blood, 
3000 r/min, the centrifugal 10 min, separate serum, test 
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the sample. Room temperature balance ELISA kit for 
30 min, put the standard and sample test enzyme label 
plate, 37°C for 2 h. Add Labeled antibody working liq-
uid, 37°C incubate for 1 h; add HRP working liquid, 
37°C incubate for 30 min; add TMB substrate solution, 
20 min later add terminated liquid, finish the reaction, 
450 nm standard wave length measure the optical den-
sity value of the tests. Use standard concentration and 
its OD value to make a standard curve, figure out the re-
gression equation, put sample OD values into the equa-
tion, calculate the TNF-α, IFN-γ, IL-2, TGF-β, IL-10 
levels. 
-Statistical analysis 
All data were processed by Origin Professional 8.5 soft-
ware. The statistical significance between the control 
and nsPEFs treatment groups was calculated by Stu-
dent’s t-test. Significance was considered when p< 0.05. 
Results  
-30 kV / cm 100 ns 200p nsPEFs inhibits tumor growth.
7 days after inoculation B16, we found the distribution 
of subcutaneous tumor (Fig. 1A). The tumor-bearing 
mice were treated by 30 KV/cm 100 ns 100 pulse, 200 
pulse, and 300 pulse respectively (Fig. 1B). the activ-
ity of mice was significantly reduced after treatment. 
Fig. 1: The change of C57BL/6 mice with B16 melanoma cells after treatment and extracted T lymphocytes from the spleen. 7 days after inocula-
tion B16, the distribution of subcutaneous tumor can be found. Tumor-bearing mice treated by nsPEFs (Fig. 1B). Untreated tumor (Fig. 1A). The 
tumor with 30 kv,100 ns,100 pulses treated (Fig. 1C); the tumor with 30 kv,100 ns, 200 pulses treated (Fig. 1D). 4 days later, extracted T lym-
phocytes from the spleen (Fig. 1E). T cells morphology under a microscope(10x) (Fig. 1F). After treatment the survival rate of T lymphocytes 
increased in 24 hours and 48 hours compared with the untreated group (P < 0.05) (Fig. 1G,H).
The mice with 300 pulses were dead. In the 100 and 
200 pulse treatment groups, the tumor size became nar-
rowed after treatment, and the area of the tumor were 
more significantly reduced in 200 times than in the 100 
pulse treatment groups (Fig. 1C,D), suggesting that the 
number of pulses was positively correlated with tumor 
ablation within the tolerance range of the mice. Accord-
ing to the efficacy of pulse therapy for melanoma. 30 
kV/cm 100 ns 200p was chose as following-up param-
eters. 4 days after treatment of tumor-bearing mice, T 
lymphocytes were extracted from the spleen cells, cells 
grow in suspension (Fig. 1E,F). The survival rate of T 
lymphocytes after treatment of nsPEFs was tasted by 
CCK-8. As is shown (Fig.1 G,H), after treatment the 
survival rate of T lymphocytes increased to 8% in 24 
hours and 10.2% in 48 hours compared with the untreat-
ed group (P< 0.05). It shows that after nsPEFs therapy 
T lymphocyte proliferate and more immune cells were 
recruited. It suggested nsPEFs enhanced the cellular 
immune function.
-nsPEFs treatment of tumor-bearing mice enhanced cel-
lular immune function and anti-tumor effects.
To further define change of immune system, the spleen 
was undertaken by flow cytometric. Compared with the 
untreated group, the content of CD3+CD4+T cells in-
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creased from 48% to 51.2%; the content of CD3+CD8+T 
lymphocytes increase from 39.6% to 40.4% (Fig. 2A). 
Treg cells reduce by 4.3% to 2.4% (Fig. 2B). MDSC 
reduced by 39.0% to 19.7% (Fig. 2C). The increased 
CD3+CD4+T can directly kill tumors, and these cells 
can cause the release of interferons and perforin to ac-
celerate the destruction of tumor cells. The decrease 
in the percentage of immunosuppressed cells indicates 
that the immunosuppressive function of the body is 
weakened after stimulation, and the ability of immune 
cells to capture tumor cells is improved. In short, the 
results suggested that nsPEFs treatment of tumor-bear-
ing mice enhanced cellular immune function and anti-
tumor effects. 
-The anti-tumor effect of nsPEFs-treated mice is related 
to the level of immune factors.
To investigate the mechanisms of T cell activation, we 
analysis the immune factor of tumor-bearing mice(non-
treatment group VS nsPEFs treatment group). As is 
shown on, after the treatment, the level of IL-2 and 
Fig. 2: The flow cytometry analysis. Compared with the untreaed group, the content of CD3+CD4+T cells and CD3+CD8+T lymphocytes were 
increased (Fig. 2A). In contrast, the cells of treg and MDSC were reduced (Fig. 2B,C) (n≥3 independent experiments).
TNF-α increased (P < 0.05) (Fig. 3A,B). the content 
of IL-10 reduced (P < 0.05) (Fig. 3C). IFN-γ, TGF-β 
increased without statistical difference (P > 0.05) 
(Fig. 3D,E). IL-2, TNF-α, and IFN-γ immune factors 
enhanced the function of tumor-killing cells such as 
CD3+CD4+T and NK cells. The experimental results 
suggested that the anti-tumor effect of nsPEFs treatment 
is related to the level of immune factors, and the func-
tion of immune cells is enhanced with the change of 
immune factors. All the data indicated the imbalance of 
cytokines plays a role of anti-tumor effect in mice. 
Discussion 
The malignant melanoma model as a classic model is 
closely related to the development of immunotherapy, 
so the model of this study is based on the C57BL/6 
mouse malignant melanoma xenograft model. This 
article successfully combines the two hot spots of cur-
rent malignant melanoma treatment. Pulse upper limit 
based on non-thermal effect is 300 ns (14). We used 
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Fig. 3: The results showed that after treatment IL-2 and TNF-α concentration increased (P < 0.05) (A,B); the level of IL-10 decreased (P< 0.05) 
(C). IFN-γ, TGF-β had a rising trend, but no statistical difference (P>0.05) (D,E). All data are presented as means± standard deviations (n≥3 
independent experiments).
a pulse width of 100 ns, a field strength of 30 Kv/cm, 
and a pulsed electric field of 100 pulse, 200 pulse and 
300 pulse with a frequency of 1 Hz as a variable for the 
treatment of malignant melanoma xenografts. We found 
that the tumor growth can be effectively inhibited with 
the treatment( 30 kV/cm ,100 ns, 200p nsPEFs). Studies 
have shown that the volume and weight of fibrosarcoma 
in mice were reduced by 60% after 8 days of treatment 
with nsPEFs (15). The nsPEFs(43 k V/cm, 20 ns, 200 p 
nsPEFs) treatment of basal cell carcinoma could gain 
therapeutic results (16). These results are consistent with 
our research. Of course, different parameters of pulsed 
electric fields are different on antitumor effects of var-
ied tumors (17-18). Previous adoptive immunotherapy 
kills tumor cells and kills normal cells that have a com-
mon antigen with tumor cells. But we utilized nsPEFs to 
trigger the autoimmune system immunity of the body, 
effectively avoiding this problem.
T lymphocyte is the key of cancer therapy (19-20). To 
evaluate this effect, in our research, the CCK-8 analy-
sis showed that nsPEFs can directly kill tumor cells by 
promoting T lymphocyte proliferation. T lymphocyte 
mainly contains cytotoxic CD8+T cells and CD4+T 
cells. Antitumor immunity involves the priming of both 
CD4+T and CD8+T. To evaluate the effect, we used 
flow cytometry for detection. The results confirmed that 
the application of nsPEFs can enhance the cytotoxic ef-
fect of immune cell to target tumor cell. Analogously, 
nuccitelli et al found that it can stimulate specific im-
mune response of tumor cells and inhibit the growth of 
tumors (21).
After confirming the effect of T lymphocyte, we evalu-
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ated Treg and MDSC. They are immunosuppressive 
cells that allow tumor cells to escape immune surveil-
lance (22-23). Patients with long-term tumor-bearing 
survival have a lower number of Treg cells and a higher 
number of cytotoxic T cells (24). Our study showed 
that conformed that 30 kV/cm, 100 ns 200pulse, 1 Hz 
electric field treatment inhibited Treg and MDSC. This 
suggests that nsPEFs may inhibit immune escape in the 
treated host except immune cell. In addition,the sys-
temic immunity contains all kinds of cytokines. Tumor 
necrosis factor-alpha can cause hemorrhage and necro-
sis of tumor cells, directly kill tumor cells, cause local 
inflammatory reaction, and promote the killing ability 
of monocyte macrophages. IL-2 and IFN-γ in mouse 
serum are mainly produced by activated Th1 cells, it 
can activate NK cells to induce T cell proliferation, Th0 
to differentiate into Th1 cells, and then produce more 
cytokines, IL-10 and TGF-β create a microenvironment 
for immune escape during the development of tumors 
(25-26). To assessment the change of cytokines affected 
by nsPEFs we used ELISA kit to perform. The results 
demonstrated that after the treatment, the level of IL-2 
and TNF-α increased, the content of IL -10 reduced. In 
short, 30 kV/cm, 100 ns 200pulse, 1 Hz electric field 
treatment can stimulate the changes of the content of 
anti-tumor immune factors and play an important role 
in assisting immune cells.
NsPEFs therapy for melanoma is similar to immuno-
therapy which reinfuse immune cells to host or a large 
immune response caused by surgical resection. Both of 
them can cause the body produce an immune response. 
According to report (27), CD4+T cells can be detected 
in both nsPEFs treated tumor and untreated secondary 
transplantation tumor. The result further confirmed that 
nsPEFs can activate tumor immune responses. Accord-
ing to this study, we can guess that nsPEFs stimulates 
the immune system indirectly. The body can not rap-
idly clear the early apoptotic cells induced by nsPEFs. It 
may has not been eliminated by phagocytes and perfo-
rin granzymes. These necrotic cells are recognized by 
the memory cells and carry out antigen presentation to 
activate the body’s immune response. However, this hy-
pothesis needs further study. Whether nsPEFs change 
the immune system directly or not? It still needs further 
study.
Our current understanding of immunology was largely 
defined in laboratory mice, partly because they are in-
bred and genetically homogeneous, can be genetically 
manipulated, allow kinetic tissue analyses to be carried 
out from the onset of disease, and permit the use of trac-
table disease models. Laboratory mice reflect relevant 
aspects of the human immune system, but, it is subject 
to the constraints of pulse electrodes and can only be 
used to treat small tumors. There is no more research on 
larger metastases. So, it has the limitations of an animal 
experimental model in its use in humans notability. The 
first-in-human safety trial of nanoelectroablation indi-
cated that this new therapy is safe and may offer a fast 
and scarless alternative to the current standard of care 
for small basal cell carcinoma tumors (28). However, 
the nanosecond pulse is also a category of high volt-
age. Although it can induce tumor cell apoptosis, on the 
other hand, it has potential harm to the organism, which 
should be highly valued by us, and the corresponding 
protective measures should be taken. It is hoped that 
this study can provide new ideas for the combination 
of physical therapy with immunotherapy in the future 
and provide a new experimental basis for the clinical 
application of nsPEFs to treat tumor. 
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